Clinical Edge Journal Scan

CRC with synchronous liver metastases: Outcomes of simultaneous laparoscopic vs. hybrid and open resection


 

Key clinical point: Compared with hybrid and open resection, simultaneous laparoscopic resection of colorectal cancer (CRC) and liver metastases offers improved postoperative outcomes and equivalent long-term oncological outcomes.

Major finding: The laparoscopic group had a lower wound complication rate than the open group (2.1% vs. 13.2%; P = .028) and a shorter postoperative hospital stay than the hybrid and open groups (8 vs. 11 days; P < .001 for both). The 5-year liver-specific recurrence rates were similar between the laparoscopic and hybrid groups ( P = .270) and between the laparoscopic and open groups ( P = .391).

Study details: The data come from a retrospective study including 647 patients who underwent simultaneous surgery for primary CRC and synchronous liver metastases and were categorized into the laparoscopic (n = 42) vs. hybrid (n = 81) and laparoscopic (n = 48) vs. open (n = 136) group sets after propensity score matching.

Disclosures: The study received no financial support. The authors declared no conflicts of interest.

Source: Lim H-K et al. Outcomes of simultaneous laparoscopic, hybrid, and open resection in colorectal cancer with synchronous liver metastases: a propensity score-matched study. Sci Rep. 2022;12:8867 (May 25). Doi: 10.1038/s41598-022-12372-5

Recommended Reading

At-home colorectal cancer testing and follow-up vary by ethnicity
MDedge Hematology and Oncology
AGA issues position statements on reducing CRC burden
MDedge Hematology and Oncology
AI-based CADe outperforms high-definition white light in colonoscopy
MDedge Hematology and Oncology
New treatment reduces risk of anal cancer in people with HIV
MDedge Hematology and Oncology
Intensified chemotherapy confers no additional benefits with panitumumab in RAS and BRAF wt mCRC
MDedge Hematology and Oncology
Atezolizumab added to FOLFOXIRI + bevacizumab seems safe and beneficial in previously untreated mCRC
MDedge Hematology and Oncology
Therapy trends in patients with mCRC after the second disease progression
MDedge Hematology and Oncology
Is iatrogenic tumor seeding a risk factor for metachronous CRC? Evidence suggests otherwise
MDedge Hematology and Oncology
Heavy drinking associated with increased risk for EOCRC irrespective of genetic risk
MDedge Hematology and Oncology
Refractory metastatic CRC: Raltitrexed plus S-1 betters regorafenib in prolonging survival
MDedge Hematology and Oncology